Abstract: There is a viscoelastic fluid. The fluid has one or more cationic surfactants selected from the group consisting of certain quaternary salts, certain amines, and combinations thereof; one or more anionic polymers/anionic surfactants; one or more of certain zwitterionic/amphoteric surfactants; and water. There is also a method of fracturing a subterranean formation. The viscoelastic fluid is pumped through a wellbore and into a subterranean formation at a pressure sufficient to fracture the formation. There is also a method for gravel packing a subterranean formation.

Abstract: An electrical connector comprises a printed circuit board module including a printed circuit board (PCB) and a plurality of electrical elements disposed on the PCB, the PCB includes a mating end for mating with a mating connector and a plurality of conductive paths electrically connecting with the electrical elements; wherein the PCB includes a fracture surface, and the plurality of conductive paths are exposed to the fracture surface.

Abstract: A pharmaceutical combination comprising (a) a compound of formula (I), or pharmaceutically acceptable salts thereof; and (b) one or more at least one compound targeting, decreasing or inhibiting the intrinsic ATPase activity of Hsp90 and/or degrading, targeting, decreasing or inhibiting the Hsp90 client proteins via the ubiquitin proteosome pathway; the uses of such combination in the treatment or prevention of proliferative diseases; and methods of treating a subject suffering.

Abstract: Diaminoguanidine derivatives in preparation of animal growth promoters used in feed. The diaminoguanidine derivatives have a structural formula as shown in formula (I), wherein R1 is methyl, ethyl, isopropyl, n-butyl, n-propyl, n-pentyl, n-octyl, n-tetradecyl, sec-butyl, 3-pentyl, cyclopentyl or benzyl. The diaminoguanidine compounds significantly improve the productivity of ducks if they are fed with the diaminoguanidine compounds. Productivity of pigs or chickens is also improved with such diaminoguanidine compounds.

Abstract: A payment processing system continuously processes transactions. Upon arrival, in real-time, a transaction is parsed and each entity is used to retrieve other previous transactions associated with that entity in order to build a link analysis web. Iteratively, each entity in the retrieved transactions is used to retrieve other associated transactions, etc. Before retrieval of associated transactions, each entity is checked whether it appears in a bypass table. If so, that entity is not used to retrieve transactions. Once built, transactions and entities within the link analysis web are analyzed to determine whether the current transaction is fraudulent. Off-line or online, risk metrics such as address mismatch rate, bank decline rate, ticket decline rate and new payment device rate, along with the proportion of a linked entity is used to determine whether that linked entity is erroneous and should be placed into the bypass table and excluded from the web.

Abstract: The disclosure relates to a pharmaceutical combination of a mdm2/4 inhibitor, namely (S)-1-(4-Chloro-phenyl)-7-isopropoxy-6-methoxy-2-(4-{methyl-[4-(4-methyl-3-oxo-piperazin-1-yl)-trans-cyclohexylmethyl]-amino}-phenyl)-1,4-dihydro-2H-isoquinolin-3-one or (S)-5-(5-Chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-6-(4-chloro-phenyl)-2-(2,4-dimethoxy-pyrimidin-5-yl)-1-isopropyl-5,6-dihydro-1H-pyrrolo[3,4-d]imidazol-4-one, and a cyclin dependent kinase 4/6 (CDK4/6) inhibitor 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide. In addition, the disclosure relates to a pharmaceutical combination product. The disclosure also relates to corresponding pharmaceutical formulations, uses and treatment methods comprising said mdm2/4 inhibitor or a cyclin dependent kinase 4/6 (CDK4/6) inhibitor.

Abstract: A clamp meter includes a meter body and a clamp jaw assembly mounted to the meter body. The clamp jaw assembly includes a first clamp jaw and a second clamp jaw which are movable in relation to each other between a closed position and an open position. In the closed position, distal ends of the first and second clamp jaws meet to define an enclosed area between the first and second clamp jaws, and in the open position, the distal ends of the first and second clamp jaws are separate from each other to define a gap allowing a wire under test to pass therethrough. The clamp meter further includes a locking member mounted within the meter body. The locking member is operable to releasably lock the first and second clamp jaws in the closed position.

Abstract: The invention provides a binding-induced DNA nanomachine that can be activated by proteins and nucleic acids. This new type of nanomachine hamesses specific target binding to trigger assembly of separate DNA components that are otherwise unable to spontaneously assemble. Three-dimensional DNA tracks of high density are constructed on gold nanoparticles functionalized with hundreds of single-stranded oligonucleotides and tens of an affinity ligand. A DNA swing arm, free in solution, can be linked to a second affinity ligand. Binding of a target molecule to the two ligands brings the swing arm to AuNP and initiates autonomous, stepwise movement of the swing arm around the AuNP surface. The movement of the swing arm generates hundreds of oligonucleotides in response to a single binding event. The new nanomachines have several unique and advantageous features over DNA nanomachines that rely on DNA self-assembly.

Abstract: A portable measurement device includes an elongated body, a stationary portion fixedly mounted to a distal end, and a movable jaw movably mounted to the distal end and movable between a closed position and an open position. In the closed position, the movable jaw and the stationary portion form a closed loop with an inner diameter of less than or equal to 10 mm. Alternatively, at least one of the movable jaw and the stationary portion has a cross-sectional diameter of less than or equal to 5 mm. In the open position, the movable jaw and the stationary portion define a gap allowing a wire under test to pass therethrough into the loop. A switch drives the movable jaw between the closed and open positions. A measurement circuit electrically coupled to the stationary portion and the movable jaw to receive and measure a sensing current generated by the closed loop.

Abstract: The present invention is directed to semiconductor processes and devices. More specifically, embodiments of the present invention provide a shaped cavity that this later to be filled with SiGe material. The shape cavity comprises convex regions interfacing the substrate. There are other embodiments as well.

Abstract: An electrical connector comprises a printed circuit board module including a printed circuit board (PCB) and a plurality of electrical elements disposed on the PCB, the PCB includes a mating end for mating with a mating connector and a plurality of conductive paths electrically connecting with the electrical elements; wherein the PCB includes a fracture surface, and the plurality of conductive paths are exposed to the fracture surface.

Abstract: A pharmaceutical combination comprising (a) an ALK inhibitor, or a pharmaceutically acceptable salt thereof, and (b) at least one HDMA-2/p53 receptor inhibitor or a pharmaceutically acceptable salt, or at least one BRaf inhibitor or a pharmaceutically acceptable salt, and optionally a pharmaceutically acceptable carrier, for simultaneous, separate or sequential administration; the uses of such combination in the treatment of cancer; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.

Abstract: Diaminoguanidine derivatives in preparation of animal growth promoters used in feed. The diaminoguanidine derivatives have a structural formula as shown in formula (I), wherein R1 is methyl, ethyl, isopropyl, n-butyl, n-propyl, n-pentyl, n-octyl, n-tetradecyl, sec-butyl, 3-pentyl, cyclopentyl or benzyl. The diaminoguanidine compounds significantly improve the productivity of ducks if they are fed with the diaminoguanidine compounds. Productivity of pigs or chickens is also improved with such diaminoguanidine compounds.

Abstract: The disclosure relates to a pharmaceutical combination of a mdm2/4 inhibitor, namely (S)-1-(4-Chloro-phenyl)-7-isopropoxy-6-methoxy-2-(4-{methyl-[4-(4-methyl-3-oxo-piperazin-1-yl)-trans-cyclohexylmethyl]-amino}-phenyl)-1,4-dihydro-2H-isoquinolin-3-one or (S)-5-(5-Chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-6-(4-chloro-phenyl)-2-(2,4-dimethoxy-pyrimidin-5-yl)-1-isopropyl-5,6-dihydro-1H-pyrrolo[3,4-d]imidazol-4-one, and a cyclin dependent kinase 4/6 (CDK4/6) inhibitor 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide. In addition, the disclosure relates to a pharmaceutical combination product. The disclosure also relates to corresponding pharmaceutical formulations, uses and treatment methods comprising said mdm2/4 inhibitor or a cyclin dependent kinase 4/6 (CDK4/6) inhibitor.

Abstract: Esters or salts of 2-hydroxy-4-propyleyclohepta-2,4,6-trienone, and applications thereof in preparation of animal antibacterial agents and growth promoters used in feed. The esters or salts of 2-hydroxy-4-propylcyclohepta-2,4,6-trienone has a structural formula as shown in formula 1 or 2: in formula 1, R1 represents heptadecyl; and in formula 2, L is sodium, potassium, calcium, magnesium, zinc, copper or manganese. The esters or salts of 2-hydroxy-4-propyleyclohepta-2,4,6-trienone, as shown in formula 1 or 2, have high stability and safety, and good antibacterial and growth promotion effects, which make them preferable to be used as animal antibacterial agents and growth promoters in feed, and have a very good application prospect in the cultivation industry.

Abstract: A semiconductor device structure is provided. The semiconductor device structure includes a semiconductor substrate. The semiconductor device structure includes a gate stack over the semiconductor substrate. The semiconductor device structure includes spacers over opposite sidewalls of the gate stack. The spacers and the gate stack surround a recess over the gate stack. The semiconductor device structure includes a first insulating layer over the gate stack and an inner wall of the recess. The semiconductor device structure includes a second insulating layer over the first insulating layer. Materials of the first insulating layer and the second insulating layer are different, and a first thickness of the first insulating layer is less than a second thickness of the second insulating layer.

Abstract: A pharmaceutical combination comprising (a) a compound of formula (I), or pharmaceutically acceptable salts thereof; and (b) one or more at least one compound targeting, decreasing or inhibiting the intrinsic ATPase activity of Hsp90 and/or degrading, targeting, decreasing or inhibiting the Hsp90 client proteins via the ubiquitin proteosome pathway; the uses of such combination in the treatment or prevention of proliferative diseases; and methods of treating a subject suffering.

Abstract: The present invention is directed to semiconductor processes and devices. More specifically, embodiments of the present invention provide a shaped cavity that this later to be filled with SiGe material. The shape cavity comprises convex regions interfacing the substrate. There are other embodiments as well.

Abstract: The present invention is directed to semiconductor processes and devices. More specifically, embodiments of the present invention provide a semiconductor device that comprises a shaped cavity formed from two trench structures, and the shaped cavity is filled with silicon and germanium material. There are other embodiments as well.

Abstract: A communication device of handling a carrier grouping comprises a storage unit for storing instructions and a processing means coupled to the storage unit. The processing means is configured to execute the instructions stored in the storage unit. The instructions comprise receiving a message for grouping at least one component carrier into a carrier group; receiving a control information for the at least one component carrier of the carrier group from a network; and performing a communication operation with the network via the at least one component carrier according to the control signal.